Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v8-FR Version v2-FR
Language French French
Date Updated 2022-10-31 2022-10-07
Drug Identification Number 02279460 02279460
Brand name APIDRA APIDRA
Common or Proper name Apidra Vials Apidra
Company Name SANOFI-AVENTIS CANADA INC SANOFI-AVENTIS CANADA INC
Ingredients INSULIN GLULISINE INSULIN GLULISINE
Strength(s) 100UNIT 100UNIT
Dosage form(s) SOLUTION SOLUTION
Route of administration SUBCUTANEOUS SUBCUTANEOUS SUBCUTANEOUS SUBCUTANEOUS
Packaging size 1 10 mL vials
ATC code A10AB A10AB
ATC description INSULINS AND ANALOGUES INSULINS AND ANALOGUES
Reason for shortage Demand increase for the drug. Demand increase for the drug.
Anticipated start date
Actual start date 2022-10-06 2022-10-06
Estimated end date 2023-01-16 2022-10-31
Actual end date
Shortage status Actual shortage Actual shortage
Tier 3 Status No No
Company comments Supply delay. Shortage can be intermittent as Sanofi may receive partial shipments, until full resolution expected on “Estimated end date”. The availability date represents estimated availability at the main Sanofi warehouse. Availability dates at a customer’s usual distributor warehouse may vary. Pharmacies are invited to communicate with their preferred distributor to obtain the product availability date.
Health Canada comments